# Geneplus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneplus

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.geneplus.cn/
- Total disclosed funding: $254M
- Latest round: Series D (Nov 29, 2025)
- Investors on record: 28

## About

Founded in 2015 and based in Beijing, China, Beijing GenePlus Technology Co., Ltd., trading as Geneplus operates as a cancer prevention testing service company. The company was co-founded by CEO Dr. Yi Xin and President Dr. Yang Ling. The company has more than 700 employees and an operating area of more than 13,000 square meters. In November 2025, Geneplus raised CNY 300 million in series D funding from returning investor Changping Captial, new investor Shaoxing Yuecheng District Science and Technology Innovation and Talent Introduction Fund and other investors.

The company operates as a cancer prevention testing service provider that develops clinical services and products for customers, such as precise drug use, curative effect monitoring, postoperative recurrence detection, and screening. Geneplus is engaged in clinical detection, medical equipment production, technology cooperation, and services, as well as the treatment and prevention of tumors. 

The company generates revenue by doing research, development and sales of its products and other related services.

The company will use the latest funding for AI multi-omics technology research and development, expansion of the biomarker innovation pipeline, and deepening of the global service network.

## Funding rounds

- Series D, Nov 29, 2025, $42M — Changkejin  Investment
- Series C, Oct 11, 2025 — CGP Investment, Changkejin  Investment
- Series C, Jul 22, 2021, $116M — CCB International, Golden Seeds, Jinmao Capital, Baidu Ventures, Chuanghehui Capital, CCB Investment Funds Management, Shenzhen Fortune Caizhi Venture, AliHealth, Yuanfeng Capital, Huajin Investment, Shengyu Investment, Junci Investment, Zhongguancun Zhongnuo Fund, Weiting Capital, Jiyuan Capital
- Series B, Nov 16, 2020, $38M — Huagai Capital, Sharewin Investment, HighLight Capital, Wisdomont Capital, Aier Healthcare Investment Group
- Series B, Sep 30, 2019, $28M — Green Pine Capital Partners, Shenzhen Huada Gene Technology Co., Ltd., CoStone Capital, Volcanics Venture, Desun Capital, UEC Group LTD
- Series A, Aug 26, 2016, $30M — Green Pine Capital Partners, Shenzhen Huada Gene Technology Co., Ltd.

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A, Series B
- Shenzhen Huada Gene Technology Co., Ltd. — Series A, Series B
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series B
- Volcanics Venture (https://capitalatlas.ai/funds/volcanics-venture) — Series B
- Desun Capital (https://capitalatlas.ai/funds/desun-capital) — Series B
- UEC Group LTD — Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series B
- Sharewin Investment (https://capitalatlas.ai/funds/sharewin-investment) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Wisdomont Capital (https://capitalatlas.ai/funds/wisdomont-capital) — Series B
- Aier Healthcare Investment Group — Series B
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series C
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series C
- Jinmao Capital — Series C
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series C
- Chuanghehui Capital (https://capitalatlas.ai/funds/chuanghehui-capital) — Series C
- CCB Investment Funds Management (https://capitalatlas.ai/funds/ccb-investment-funds-management) — Series C
- Shenzhen Fortune Caizhi Venture — Series C
- AliHealth — Series C
- Yuanfeng Capital (https://capitalatlas.ai/funds/yuanfeng-capital) — Series C
- Huajin Investment — Series C
- Shengyu Investment — Series C
- Junci Investment (https://capitalatlas.ai/funds/junci-investment) — Series C
- Zhongguancun Zhongnuo Fund — Series C
- Weiting Capital — Series C
- Jiyuan Capital (https://capitalatlas.ai/funds/jiyuan-capital) — Series C
- CGP Investment — Series C
- Changkejin  Investment — Series C, Series D